Unlock instant, AI-driven research and patent intelligence for your innovation.
A kind of montelukast sodium granule and preparation method thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of montelukast sodium and granules, applied in the field of medicine, can solve problems such as hidden safety hazards and human harm, and achieve the effect of slowing down the impact and taking it safely.
Inactive Publication Date: 2016-09-21
珠海天翼医药技术开发有限公司
View PDF6 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
The cis-isomer and montelukast are harmful substances, which are harmful to the human body, especially children, and have great potential safety hazards
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0024]
[0025]
[0026] According to the above components, proceed as follows:
[0027] (1), stomach-soluble acrylic resin E (PO), titanium dioxide, talcum powder, polyethylene glycol are made into 10% gastric-soluble acrylic resin ethanol solution;
[0028] (2) After the raw materials are evenly mixed with mannitol and microcrystalline cellulose, use 1 / 3 of 10% gastric-soluble acrylic resin ethanol liquid to make a soft material, centrifugally spheronize, and dry at 40 OC to obtain particles below 60 mesh;
[0029] (3), the particles are placed in a fluidized bed, coated with 2 / 3 of 10% gastric-soluble acrylic resin coating liquid, and dried at 40°C for 2 hours;
[0030] (4), take the dried granules, add strawberry essence and aspartame and mix evenly;
[0031] (5) After the content was determined, the finished product 1 was obtained by dispensing according to the specification of 0.5 g containing 4 mg of montelukast.
Embodiment 2
[0033] Raw materials
[0034] According to the above formula, adopt the same preparation method as in Example 1, the difference is only in the replaced components, so as to obtain the finished product 2.
Embodiment 3
[0036]
[0037]
[0038] According to the above formula, adopt the same preparation method as in Example 1, the difference is only in the replaced components, so as to obtain the finished product 3.
[0039] According to above embodiment, carry out test, specifically as follows:
[0040] Stability research between the present invention and commercially available samples
[0041]
[0042] It can be seen from the above results that the stability of the product of the present invention is much stronger than that of the commercially available samples, and it is safer to use.
[0043] The release degree of the present invention and commercially available samples in artificial gastric juice
[0044] sampling time
[0045] As can be seen in this table, its release is stable and easy to absorb.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention provides a montelukast granule. The montelukast granule is prepared from the components in percentage by weight: 1-1.5 percent of montelukast, 50-60 percent of filler, 10-30 percent of gastric-soluble acrylic acid resin, 5-10 percent of talc, 1-3 percent of polyethylene glycol, 10-20 percent of titanium dioxide and 0.2-0.5 percent of flavoring agent. With the adoption of the montelukast granule, with the gastric-soluble acrylic acid resin as a coating material and the titanium dioxide as an opacifying agent, as the gastric-soluble acrylic acid resin is difficult to be dissolved in water, and due to the shading action of the titanium dioxide, the influence on the gastric-soluble acrylic acid resin under illumination is retarded, so that the montelukast granule is stable within 1 hour as well as is more safe and convenient to take. The invention also discloses a preparation method of the montelukast granule.
Description
technical field [0001] The invention relates to the field of medicine, in particular to a montelukast sodium granule, and also relates to a preparation method of the montelukast sodium granule. Background technique [0002] Montelukast sodium is an oral selective leukotriene receptor antagonist that specifically inhibits the cysteinyl leukotriene (CysLT1) receptor. [0003] Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are mediators of inflammation released by a variety of cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene (CysLT) receptors. Cysteinyl leukotriene type I (CysLT1) receptors are distributed in the human airways (including airway smooth muscle cells and airway macrophages) and other proinflammatory cells (including eosinophils and certain bone marrow stem cells) . CysLTs are associated with the pathophysiological processes of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects inclu...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More